louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05695729: Effects of Plyometrics Versus Conventional Exercises on Speed, Strength, and Injury Prevention in Bowlers.
Official title: Effects of Upper Body Plyometrics Versus Conventional Exercises on Speed, Strength and Injury Prevention in Bowlers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sports Injury
Sports Physical Therapy
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-01-25
Enrollment: 36
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To compare the effects of upper body plyometric versus conventional exercises on speed, strength, and injury prevention in bowlers

Detailed description: Bowling action is a highly skilled activity acquired over the year. A bowler needs speed and strength to challenge the batsman but the conventional protocols they follow for the speed and strength are not specific to their bowling actions. Bowling can result in different types of upper extremity injuries, such as rotator cuff sprains, impingement and stress fractures. There are many injury prevention programs such as electrostimulation training, resistance training, and plyometric training that can be used to treat upper limb injuries and improve maximal strength.

Plyometric training can be done by overhead athletes to improve the effectiveness of throwing activity and to strengthen the rotator cuff muscles to prevent shoulder injury from overhead throwing activity.

This study aims to evaluate the effectiveness of upper limb plyometric exercises on speed, strength and injury prevention in comparison with conventional exercises.

Eligibility criteria: Inclusion Criteria:

* Players bowling for at least one year
* Bowlers age 18 to 35 years

Exclusion Criteria:

* Any acute or chronic musculoskeletal injuries
* Any surgery in 6 months

Primary outcomes:
measure: Strength
timeFrame: 8 weeks
measure: Speed
timeFrame: 8 weeks
Secondary outcomes:
measure: Injury Prevention
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Quetta
country: Pakistan
facility: Ayub Stadium
state: Balochistan
Study officials:
affiliation: Riphah International University
name: Saad Rauf, Ph.D*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00612729: Light Filters in Intraocular Lenses (IOLs) and Its Influence on Colour and Contrast Vision.
Official title: Influence of Light-filters in IOLs on Color Perception and Contrast Acuity. A Randomized, Double-masked Study With Intraindividual Comparison.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Cataract
Keywords: intraocular lens
light filtering intraocular lens
contrast acuity
color vision
Lead sponsor: Hospital Hietzing
Sponsor class: OTHER
First posted: 2008-02-12
Enrollment: 32
Sex: ALL
Minimum age (years): 55
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Visible-light-filtering IOLs are implanted increasingly often in cataract surgery. Several studies examined the effect of light-filters on contrast and colour vision. However, the study outcomes were varying. The present study investigated the effect of two light-filtering IOL on colour perception and contrast acuity using highly sensitive measurement methods.

Detailed description: Prospective, randomized, double-masked study with intraindividual comparison. Implantation of a Polylens Y30 IOL in one eye and an Orange Series Model PC 440 Y in the contralateral eye.

Eligibility criteria: Inclusion Criteria:

* bilateral age-related cataract
* age 55 to 80 years
* expected postoperative visual acuity of at least 1.0

Exclusion Criteria:

* amblyopia
* corneal scars
* diabetes
* arterial hypertonia
* pseudoexfoliation-syndrome
* earlier ocular surgeries or laser treatments
* intraocular tumors
* color abnormalities
* expected postoperative visual acuity lower 1.0

Primary outcomes:
measure: contrast acuity
timeFrame: 3 month after surgery
Secondary outcomes:
measure: visual acuity and color vision
timeFrame: 3 month after surgery
measure: colour perception
timeFrame: 3 month after surgery
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Ophthalmology, Hietzing Hospital
Study officials:
affiliation: Dept of Ophthalmology, Hietzing Hospital, Vienna, Austria
name: Matthias G Wirtitsch, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dept of Ophthalmology, Hietzing Hospital, Vienna, Austria
name: Nadja Karnik, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02489929: Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine
Official title: Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplasic Syndrom or an Acute Myeloid Leukemia and Treated by Azacytidine
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Myeloid Leukemia
Myelodysplastic Syndromes
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2015-07-03
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Myelodysplastic syndrome (MDS) is a group of medical conditions derived from progressive bone marrow failure that result in ineffective production of blood cells. Depending on the severity, MDS reduces the quality of life to the point of being life-threatening. There is a probability of death at all stages of the disease, due to complications and co-morbidities, with progression to acute myeloid leukemia (AML) being the worst evolution. Azacytidine is a nucleosidic analog with original epigenetic mechanism of action that is widely used for treating a variety of myelodysplasic syndromes. Although generally well tolerated, severe and sometimes life-threatening toxicities were unexpectedly observed in some patients. Genetic polymorphism affecting cytidine deaminase (CDA), the liver enzyme responsible for azacytidine detoxification step, could be responsible for poor clinical outcome due to on the one hand to severe toxicities in deficient patients, and on the other hand on treatment failure in ultrametabolizer patients.This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment.


Eligibility criteria: Inclusion Criteria:

* The patients have to be capable of submitting themselves at the rate of the visits, in the plan of treatmen, in the balance assessments of laboratory and other procedures of the study.
* Patient treated by azacytidine

Exclusion Criteria:

* Patients having an infection unchecked who could compromise the participation in the study
* Patients having other grave and/or unchecked concomitant diseases which could compromise the participation in the study

Primary outcomes:
measure: Number of survival without progress of the disease
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique - Hopitaux de Marseille
Study officials:
affiliation: AP-HM
name: Regis COSTELLO, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00524329: Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage
Official title: SYNCHRONISE: Esomeprazole 20 mg Once Daily for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs in Dutch General Practice: The Influence of Risk-Factors for NSAID-Associated GI Damage on Sympton Response
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heartburn
Keywords: upper GI-symptoms
heartburn
NSAID
risk
PPI
Bloating
Regurgitation
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-09-03
Enrollment: 1220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting at general practitioner

Brief summary: The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage (as determined by the treating physician).


Eligibility criteria: Inclusion Criteria:

* Patient with upper gastro-intestinal complaints (defined as heartburn and/or regurgitation and/or nausea and/or bloated feeling)and treatment with esomeprazole 20mg once daily is started because of this (consult 1). Upper gastro-intestinal complaints are thought to be related to NSAID use
* Patient is using an NSAID\*\* with the following conditions:

  * NSAID use has started at least one week before 1st consultation and is expected to be continued unchanged during the coming period (at least until consult 2)
  * NSAID is taken at least 3 days a week

(\*\*)OTC or Prescription NSAID

(\*\*)Conventional NSAID or COX-2 selective NSAID

Exclusion Criteria:

* Use of a PPI and/or H2RA in the month preceding the study
* A history of reflux disease, not related to NSAID use

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca
name: Andrea Sellink
role: STUDY_DIRECTOR
affiliation: AstraZeneca
name: N van den Berk
role: STUDY_CHAIR
References:
Clinical trial NCT00996229: Effects of Dietary Interventions on the Aging Brain
Official title: Phase IV Interventional Study: Effects of Dietary Interventions on Brain Functions in Healthy Elderly People
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Healthy
Keywords: Diet
elderly
cognition
prevention
cognitive decline
Lifestyle
Lead sponsor: University Hospital Muenster
Sponsor class: OTHER
Collaborators: name: Charite University, Berlin, Germany
First posted: 2009-10-16
Enrollment: 300
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The researchers will investigate whether caloric restriction or dietary supplementation could provide positive effects on general brain functions in healthy elderly people.

Detailed description: The age-related degradation of cognitive functions even to the point of neurodegenerative disorders such as Alzheimer's disease are a growing public-health concern with devastating effects.

Referring to animal data, empirical studies, and pilot human trials, a healthy diet rich in unsaturated fatty acids and low in calories should improve cognitive functions such as learning and memory. To test this hypothesis, the researchers study general brain functions in healthy elderly subjects (50-80 years old) during a short term diet.

Eligibility criteria: Inclusion Criteria:

* healthy subjects
* 50-80 years old
* moderate to heavy weight (BMI 25-30)
* must be able to change diet/take supplements at home

Exclusion Criteria:

* diabetes
* younger than 50 years
* BMI \< 25
* psychiatric medication
* severe disease
* MMSE \< 26
* eating disorders

Primary outcomes:
measure: Auditory verbal Learning Task
timeFrame: Baseline (timepoint 0), after 6 months (timepoint 6 months)
Secondary outcomes:
measure: Functional/Structural brain changes
timeFrame: Baseline (timepoint 0), after 6 months (timepoint 6 months)
measure: Plasma biomarkers
timeFrame: Baseline (timepoint 0), after 6 months (timepoint 6 months)f intervention
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Department of Neurology, Charité Universitätsmedizin Berlin
Study officials:
affiliation: Charite University, Berlin, Germany
name: Agnes Flöel, Professor
role: STUDY_CHAIR
affiliation: Charite University, Berlin, Germany
name: Veronica Witte, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05678829: Reproductive Health and Family Planning
Official title: A Different Method in Reproductive Health and Family Planning: "Virtual Reality Application''
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Virtual Reality
Reproductive Health
Lead sponsor: Erzurum Regional Training & Research Hospital
Sponsor class: OTHER_GOV
First posted: 2023-01-10
Enrollment: 130
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The aim of this study is to measure the knowledge and attitude levels of women who play a key role in society on reproductive health and family planning, and to determine the changes in their attitudes and behaviors after face-to-face training with virtual reality application.

Detailed description: In a three-month period, using the virtual reality application prepared for the individuals in the Experimental 1 group, it will be explained for an average of 40 minutes in a time period where they are suitable, through the trainings prepared according to the subjects. The literature will be scanned and appropriate educational materials will be created, and animations will be used to support education. The trainings for the Experiment 1 group will continue in accordance with the training titles according to the weeks, using virtual reality glasses. Modern family planning methods will be shown in detail through virtual reality glasses, three dimensions of the methods will be shown and supported by videos.

By using the training room of the family health center specified for the individuals in the Experimental 2 group, training content covering the subjects of reproductive and health and family planning methods will be prepared, and the days when women are suitable will be determined, and each training will be given for 40 minutes with face-to-face classical training method. Educational subjects will be continued in parallel with Experiment 1 group by using Ministry of Health hand brochures and training materials for Experiment 2 group.

Eligibility criteria: Inclusion Criteria:

-Being over 20 years old

* Married,
* Being literate,
* Not using modern family planning methods

Exclusion Criteria:

-Being under 20 years old

* not being married
* Not volunteering to participate in the study
* Using modern family planning method
* Not being able to attend the trainings at any stage of the research

Primary outcomes:
measure: Married Women's Reproductive Health Protective Attitudes Scale
timeFrame: two week
measure: Family Planning Scale
timeFrame: Two week
Secondary outcomes:
Other outcomes:
Locations:
city: Erzurum
country: Turkey
facility: Ataturk Unıversity
state: Yakutiye
Study officials:
affiliation: Ataturk University
name: Sümeyye Betül Sönmez
role: STUDY_CHAIR
References:
Clinical trial NCT03965429: Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation
Official title: Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Malignant Hemopathy
Keywords: malignant hemopathy
allogeneic hematopoietic stem cell transplant
blood collection
Lead sponsor: Institut Paoli-Calmettes
Sponsor class: OTHER
Collaborators: name: INSERM-U1068
First posted: 2019-05-29
Enrollment: 1020
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population is male and / or female over 18 years of age with hematologic malignancies receiving allogeneic hematopoietic stem cell transplantation and corresponding donors.

Brief summary: Description of the evolution of the biological characteristics of immune blood populations and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell transplantation.

Detailed description: a more in-depth analysis of the different immune cell sub-populations as well as serum markers (cytokines) would provide a better understanding of post-allograft immune reconstitution mechanisms and identify potential immunologic biomarkers predictive of GVH or relapse.

Eligibility criteria: Inclusion Criteria:

1. Allogeneic hematopoietic stem cell transplant for hematological malignancy
2. Patients 18 years of age or older
3. Signed consent to participation
4. Membership in a social security scheme, or beneficiary of such a scheme.

Exclusion Criteria:

* A person of legal age subject to a legal protection measure (major under guardianship, curatorship or court bail), or unable to express consent (language criteria included).

Primary outcomes:
measure: Evolution of the immune blood populations in patients who have received allogeneic hematopoietic stem cell transplantation.
timeFrame: 5 years after HSC transplantation
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Institut Paoli-Calmettes
state: Bouches-du Rhône
Study officials:
affiliation: Institut Paoli-Calmettes
name: Raynier Devillier, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00745329: The Effect of Infliximab on Sperm Quality
Official title: The Effect of Infliximab,Adalimumab, Azathioprines and 5-Aminosalicylate on Semen Quality in Men With Inflammatory Bowel Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Crohn's Disease
Ulcerative Colitis
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2008-09-03
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with inflammatory bowel disease (IBD) and healthy volunteers

Brief summary: Background: The treatment of inflammatory bowel diseases (IBD) is based mainly on 3 compounds: 1- 5 aminosalysilates . 2- immunomodulators (Azathioprines). 3- Biologic therapies (Infliximab, Adalimumab) . There are no established data in the literature whether these therapies effects sperm quality. Given that a large number of the patients are young men in the reproductive stage of their lives , It of importance to investigate these effect.

Aim: To investigate the effect of chronic treatment of any of the three therapy mentioned above, on sperm quality .


Eligibility criteria: Inclusion Criteria:

* Male above the age of 18
* Capable of giving informed consent
* Diagnosed with IBD at least 3 months
* Patients that are going to start a treatment with on of the following groups: 5ASA, Azathioprines, infliximab or ADAlimumab
* Patients that are treated with therapies mentioned in article 4 for at least 3 months

Exclusion Criteria:

* Male younger than 18

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00646529: Long-Term Safety of Symbicort in Asthmatic Children - SAPLING
Official title: A Six Month, Randomized, Open-Label, Safety Study of Symbicort (160/4.5mcg) Compared to Pulmicort Turbuhaler in Asthmatic Children Aged Six to Eleven Years - SAPLING
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Keywords: asthma
children
Symbicort
budesonide/formoterol
Pulmicort
budesonide
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-03-28
Enrollment: 175
Sex: ALL
Minimum age (years): 6
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety of Symbicort compared to Pulmicort in asthmatic children aged 6 to 11 years


Eligibility criteria: Inclusion Criteria:

* At least 6 and maximally 11 years of age
* Diagnosis of asthma
* Baseline lung function tests as determined by protocol and required and received daily treatment with inhaled corticosteroids for at least 4 weeks prior to study start

Exclusion Criteria:

* Has required treatment with any non-inhaled corticosteroids within the previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
* Has had cancer in the previous 5 years or has a significant disease that may put the patient at risk in this study

Primary outcomes:
measure: Long term safety profile of Symbicort compared to Pulmicort as determined by safety assessments detailed in the protocol
timeFrame: 4 assessments within 26 week treatment period
Secondary outcomes:
measure: Compare health economic outcomes and quality of life between patients treated with Symbicort and Pulmicort
timeFrame: 4 assessments within 26 week treatment period
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca
name: Catherine Bonuccelli
role: STUDY_DIRECTOR
References:
Clinical trial NCT04645329: Immobilization in Reverse Shoulder Prosthesis
Official title: Should Patients Undergoing Reverse Shoulder Prostheses Due to Arthropathy of the Rotator Cuff be Immobilized? Randomized Prospective Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Rotator Cuff Tear Arthropathy
Lead sponsor: Hospital del Mar
Sponsor class: OTHER
First posted: 2020-11-27
Enrollment: 50
Sex: ALL
Minimum age (years): 65
Maximum age (years): 85
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized prospective study. (computer-generated randomization list and saved in opaque envelopes)
Primary purpose: TREATMENT

Brief summary: Reverse shoulder prostheses are the treatment of choice in elderly patients with rotator cuff arthropathy. Traditionally these patients have been immobilized for 3 weeks in the immediate postoperative period in order to have good pain control. However, there are no studies that determine the most appropriate period of immobilization. In fact, patients undergoing this type of surgery begin rehabilitation exercises within 24 hours of surgery without experiencing increased pain or requiring specific analgesic treatment. There is a demand in the elderly to limit immobilization time as much as possible, as some live alone and need to be self-sufficient and others have dependents. It would be good to know if it is really necessary to make an immobilization in these patients undergoing this type of surgery.


Eligibility criteria: Inclusion Criteria:

* patients undergoing primary surgery of inverted prosthesis for rotator cuff arthropathy.
* age between 65-85 a.
* without inflammatory pathologies (rheumatoid arthritis, psoriatic arthritis, ...)
* acceptance to be part of the study.

Exclusion Criteria:

* prosthetic surgery prior to the affected limb.
* other indications of reverse prosthesis other than rotator cuff arthropathies (acute fractures, sequelae fractures, tumor surgery, prosthetic revision surgeries).
* no acceptance to participate in the study.

Primary outcomes:
measure: Change in Pain control (visual analogical scale)
timeFrame: determination of pain the day of the surgery, and then 24hours, 48hours, 7 days, 3-weeks, 3 months, 6 months, 1 year, 2 years postoperatively.
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital del Mar
Study officials:
affiliation: Chief Clinic of Parc de Salut Mar
name: Carlos Torrens, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: